A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
about
Gene aberrations for precision medicine against lung adenocarcinomaBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerThe minority report: targeting the rare oncogenes in NSCLCTargeted therapies in development for non-small cell lung cancerPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCCIViC databaseThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerGenomics driven-oncology: challenges and perspectivesTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRIdentification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.RET fusion gene: translation to personalized lung cancer therapyEGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.RET fusion as a novel driver of medullary thyroid carcinomaMolecularly targeted therapies in non-small-cell lung cancer annual update 2014RET-targeting molecular stratified non-small-cell lung cancers.A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomasCytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.Landscape of gene fusions in epithelial cancers: seq and ye shall find.Identification and characterization of RET fusions in advanced colorectal cancerPersonalizing therapy in advanced non-small cell lung cancerNovel targets in non-small cell lung cancer: ROS1 and RET fusionsSystemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinomaTyrosine kinase gene rearrangements in epithelial malignancies.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwayRET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.Emerging protein kinase inhibitors for non-small cell lung cancer.Prognostic and predictive biomarkers in lung cancer. A review.Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.Emerging targeted therapies in non-small cell lung cancer.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
P2860
Q26749348-1E504CD7-BCAB-4405-88FC-3E7EB3D116A5Q26851421-B3B23DA7-86C6-46A1-A38B-13CE1BCACEBEQ26851636-69B8137C-E856-4D00-97B4-653E725482CCQ27022852-B80A0AAC-4873-4BAB-84C5-B8C048A86099Q27025970-CF9E680B-EC26-4A99-82A5-F24261E2EAF8Q27612411-97BB5FFF-227F-44AD-BFE3-8A8A50C9E092Q28067196-AEEEDD7E-1203-4316-A645-4C8521D7119EQ28081770-FEA5CD68-4FB8-4E12-BFAF-5F5A5C4CDCA4Q28083446-2D4EFCB2-C681-49A5-8AC4-87AA9539ACC7Q28086993-B4D092B5-D7BC-4D70-8CC8-649797838493Q28830947-CBF3EBFE-1BF5-4FCB-86BB-2784ECAAE4C5Q30381368-3962B4A2-A397-4D7B-BBCA-0B549247608DQ33560928-869504DC-50C0-4EF4-A8DC-65AC712EB46CQ33711282-ED7E3385-2121-4F0C-9989-25DF2CB5CEF6Q34250003-BFC9B315-5A65-4D72-AF9F-68DA6DBD1054Q35096831-A46F0263-BDDF-44E9-AA7C-B778504B9284Q35136424-42EA9C52-A50B-4C8A-A55A-7CB4FA2F2F6CQ35200445-65671756-8C6A-457F-8D34-1D4FA78D3D53Q35545693-45307CB6-CE26-4F65-A423-E0F8FE3DA4B9Q35951226-3EF60C90-0300-4C37-957D-B47892F8E157Q36135533-450805A7-56CD-41AA-BC2A-D9AAEECE5BC8Q36214500-2857E638-8FB7-4DD3-AA20-95A1DE6C3FE2Q36356699-C2ACE38D-2FF2-46F7-87C1-2B29CEF8D730Q36383369-658A4332-1A58-4EA4-B67B-5B5493B47A03Q36557174-2EDE9265-B50A-432F-8AB6-914FCFAD1B62Q36811453-1682961D-04D2-4F08-90AB-05AF7CFAF905Q37038500-ED9C1C8A-FF3D-4562-BDCB-DC5E27231E80Q37204286-B7D7121E-D568-42CE-AE51-0C24E2C6CE46Q37392650-A0D7CFE6-8D71-4F56-ABE3-44E1D2F3BD30Q37515966-5E72CE9E-5A0C-42E4-8914-60D8FC923280Q37644847-DCF1A033-CBFE-44AB-BB0E-A9F0B987D52EQ37650677-F852E39D-38BF-4EC4-AC7C-E85EC0AE3A61Q38172608-B857B52D-3BB1-4A9B-81CF-AA22572BF2C5Q38178187-7E78DE73-CF7F-45AD-88ED-3A3CFAC11F27Q38203956-49C95DF9-1B8D-4960-9CFB-252C261891B3Q38245669-A842E46F-D4BF-4A99-9451-7C32D7830B66Q38433965-148D9424-76D8-4003-AC61-D0D8032E627DQ38587521-EC7EE12F-ECD3-4F2E-B15D-F938B0C7AB13Q38653045-80D27425-945A-474A-B979-A6C3EA36A550Q38653663-CA44DB27-DA8E-46D7-B7E5-764C64B1909C
P2860
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@ast
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@en
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@nl
type
label
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@ast
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@en
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@nl
prefLabel
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@ast
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@en
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@nl
P2093
P3181
P1476
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
@en
P2093
Astrid Hirschmann
Franziska Aebersold Keller
Joachim Diebold
Klaus Strobel
Oliver Gautschi
Stefan Aebi
Thilo Zander
P3181
P356
10.1097/JTO.0B013E31828A4D07
P577
2013-05-01T00:00:00Z